Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Padcev (enfortumab vedotin)
- ublituximab
Interactions between your drugs
enfortumab vedotin ublituximab
Applies to: Padcev (enfortumab vedotin), ublituximab
Using ublituximab together with enfortumab vedotin may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Of particular concern is an infection known as progressive multifocal leukoencephalopathy (PML), which is a rare but serious viral infection of the brain that may lead to disability and death. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Let your doctor know if you develop signs and symptoms of infection such as fever, chills, sore throat, shortness of breath, blood in phlegm, weight loss; yellow skin, severe fatigue, diarrhea, vomiting, body aches; and pain or burning during urination. Also, seek immediate medical attention if you experience progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, confusion, or changes in thinking, memory, and personality, as these may be early symptoms of PML. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Bavencio
Bavencio (avelumab) is a cancer medicine that interferes with the growth and spread of cancer cells ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Mutamycin
Mutamycin is used for bladder cancer, pancreatic cancer, stomach cancer
Erdafitinib
Erdafitinib is used for bladder cancer, urothelial carcinoma
Avelumab
Avelumab is used for merkel cell carcinoma, renal cell carcinoma, urothelial carcinoma
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.